NewsBenzingaLes essais STOP-HS1 et STOP-HS2 évaluant l’innocuité et l’efficacité du povofortay chez des patients atteints d’HS modérée à sévère ont atteint le critère d’évaluation principal. Les essais STOP-HS1 et STOP-HS2 évaluant l’innocuité et l’efficacité du povofortay chez des patients atteints d’HS modérée à sévère ont atteint le critère d’évaluation principal. Benzinga 2026.11.16 21:36 (GMT+0) Open on Benzinga Other news Why Microsoft Thinks Smaller, Cheaper AI Can Beat Claude and GPT Here’s How Much You Would Have Made Owning Royal Caribbean Group Stock In The Last 15 Years Nvidia says its open-source AI strategy remains intact after Jensen Huang’s exit $1000 Invested In Teck Resources 5 Years Ago Would Be Worth This Much Today 'Microsoft Executive Says Nvidia Drama Could Boost Rival Chips'- Bloomberg Nvidia says it doesn’t plan to reappoint Jensen Huang as CEO